Drug intelligence / Profile preview

acamprosate calcium + D-cycloserine

Development stage
Preclinical
Lead developer
Confluence Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Acamprosate calcium + D-cycloserine is a preclinical-stage, oral small molecule combination therapy being developed by Confluence Pharmaceuticals. The drug combines acamprosate calcium (calcium N-acetylhomotaurinate), which acts as a GABA-A receptor facilitator and NMDA receptor modulator, with D-cycloserine, a GABA-A agonist and NMDA receptor partial agonist. Formulated as a sustained-release oral product, the combination is designed to restore the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission. It is primarily being investigated for the treatment of neurodevelopmental and neuropsychiatric conditions, including Fragile X Syndrome (FXS), Autism Spectrum Disorders (ASD), and the maintenance of abstinence in Alcohol Abuse.

Other names
Acamprosate calcium/D-cycloserine combinationCombination Sustained Release Product of Acamprosate Calcium and D-Cycloserine
02

Targets

GRIN1 (NMDA receptor subunit 1)N-methyl-D-aspartate receptor polyamine modulatory site

Beyond the preview

Go deeper on acamprosate calcium + D-cycloserine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acamprosate calcium + D-cycloserine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call